APP and Alzheimer disease: Experiments by Huang et al. [132] have shown that oral administration of GLPs can promote NPC proliferation and neurogenesis in APP/PS1 transgenic AD mice, alleviate cognitive deficits, and reduce Aβ amyloid deposition.